New thrombopoietin receptor agonist (Lusutrombopag) is more effective in impaired renal function patients with chronic liver disease.

CONCLUSION: This study revealed that Lusutrombopag was more sufficiently effective in CLD patients compared with platelet transfusion and that renal function is independent predictor of increase. Factors indicative of renal function significantly and negatively correlated with increase in platelets.
PMID: 32238734 [PubMed - as supplied by publisher]

Source: Journal of Nippon Medical School - March 30, 2020 Category: Universities & Medical Training Authors: Takeuchi H, Furuichi Y, Yoshimasu Y, Kasai Y, Abe M, Sugimoto K, Itoi T Tags: J Nippon Med Sch Source Type: research